Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

50.35USD
15 Feb 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$50.35
Open
$49.81
Day's High
$50.37
Day's Low
$49.64
Volume
2,201,283
Avg. Vol
1,600,706
52-wk High
$54.56
52-wk Low
$41.23

Latest Key Developments (Source: Significant Developments)

Novo Nordisk Q4 Operating Profit Lags Analyst Expectations
Friday, 1 Feb 2019 01:30am EST 

Feb 1 (Reuters) - NOVO NORDISK A/S ::SAYS FOR 2019, SALES GROWTH IS EXPECTED TO BE 2-5% MEASURED IN LOCAL CURRENCIES.FY 2018 SALES 111.8 BILLION DKK VERSUS 111.9 BILLION DKK SEEN IN REUTERS POLL.SAYS THIS INCLUDES PREVIOUSLY COMMUNICATED NEGATIVE IMPACT FROM CHANGES IN FUNDING OF MEDICARE PART D COVERAGE BY APPROXIMATELY DKK 2 BILLION.FY 2018 OPERATING PROFIT 47.2 BILLION DKK VERSUS 47.8 BILLION DKK SEEN IN REUTERS POLL.SAYS SALES GROWTH REPORTED IN DANISH KRONER IS EXPECTED TO BE 2 PERCENTAGE POINTS HIGHER THAN IN LOCAL CURRENCIES.SAYS OPERATING PROFIT GROWTH IS EXPECTED TO BE 2-6% MEASURED IN LOCAL CURRENCIES.SAYS OPERATING PROFIT GROWTH REPORTED IN DANISH KRONER IS EXPECTED TO BE 4 PERCENTAGE POINTS HIGHER THAN IN LOCAL CURRENCIES.SAYS BOARD OF DIRECTORS HAS ADJUSTED LONG-TERM FINANCIAL TARGET FOR OPAT/NOA FROM 125% TO 80% TO REFLECT NEW ACCOUNTING PRINCIPLES FOR HANDLING OF LEASES (IFRS 16) AS WELL AS INVESTMENT LEVEL IN TANGIBLE AND INTANGIBLE ASSETS.BOARD OF DIRECTORS WILL PROPOSE A FINAL DIVIDEND OF DKK 5.15 FOR 2018 PER SHARE OF DKK 0.20.SAYS FURTHER, TO REFLECT INVESTMENT LEVEL, CASH TO EARNINGS TARGET IS ADJUSTED FROM 90% TO 85%.SAYS LONG-TERM FINANCIAL TARGET FOR OPERATING PROFIT GROWTH REMAINS UNCHANGED.BOARD OF DIRECTORS INTENDS TO INITIATE A NEW 12-MONTH SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION.  Full Article

Orphazyme says Novo Holdings Holds Total 3 Mln Shares In Co
Wednesday, 30 Jan 2019 01:48pm EST 

Jan 30 (Reuters) - Orphazyme A/S ::REG-MAJOR SHAREHOLDER ANNOUNCEMENT.NOVO HOLDINGS A/S HOLDS TOTAL OF 3 MILLION SHARES IN COMPANY, CORRESPONDING TO 14.97% OF SHARE CAPITAL AND VOTING RIGHTS IN CO.  Full Article

Novo Nordisk - Xultophy now available in Canada to support improved glycemic control, an issue facing 50 per cent of canadians with type 2 diabetes
Wednesday, 23 Jan 2019 08:00am EST 

Jan 23 (Reuters) - Novo Nordisk A/S ::XULTOPHY® NOW AVAILABLE IN CANADA TO SUPPORT IMPROVED GLYCEMIC CONTROL, AN ISSUE FACING 50 PER CENT OF CANADIANS WITH TYPE 2 DIABETES.  Full Article

DKSH Holding Signs Distribution Agreement With Novo Nordisk Pharmatech
Wednesday, 16 Jan 2019 01:07am EST 

Jan 16 (Reuters) - DKSH Holding AG ::SIGNS DISTRIBUTION AGREEMENT WITH NOVO NORDISK PHARMATECH FOR ELEVEN MARKETS IN ASIA PACIFIC.  Full Article

Novo Nordisk And Staten Biotechnology To Collaborate To Develop Novel Treatment For Dyslipidaemia
Monday, 17 Dec 2018 02:35am EST 

Dec 17 (Reuters) - Novo Nordisk A/S ::SAYS STATEN BIOTECHNOLOGY B.V. AND NOVO NORDISK A/S ANNOUNCE COLLABORATION TO DEVELOP NOVEL TREATMENT FOR DYSLIPIDAEMIA.SAYS NORDISK HAS RIGHT TO ACQUIRE STATEN BIOTECHNOLOGY AND GAIN WORLDWIDE RIGHTS TO STT-5058.STATEN BIOTECHNOLOGY AND ITS SHAREHOLDERS WILL POTENTIALLY RECEIVE SIGNING AND EXERCISE FEES, RESEARCH AND DEVELOPMENT FUNDING, AND MILESTONE PAYMENTS OF UP TO 430 MILLION EUROS.  Full Article

Novo Nordisk Says Oral Semaglutide Study Shows Significant Reduction In Cardiovascular Death
Friday, 23 Nov 2018 10:08am EST 

Nov 23 (Reuters) - NOVO NORDISK A/S SAYS::ANNOUNCED HEADLINE RESULTS FROM LAST GLOBAL PHASE 3A TRIAL, PIONEER 6, FOR ORAL SEMAGLUTIDE, AN INVESTIGATIONAL GLP-1 ANALOGUE TAKEN ONCE DAILY AS A TABLET.ORAL SEMAGLUTIDE DEMONSTRATES FAVOURABLE CARDIOVASCULAR SAFETY PROFILE AND SIGNIFICANT REDUCTION IN CARDIOVASCULAR DEATH AND ALL-CAUSE MORTALITY IN PEOPLE WITH TYPE 2 DIABETES IN THE PIONEER 6 TRIAL.TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING NON-INFERIORITY OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO, BOTH IN ADDITION TO STANDARD OF CARE.EXPECTS TO FILE ORAL SEMAGLUTIDE FOR REGULATORY REVIEW IN US AND EU IN FIRST HALF OF 2019.MACE RESULTS DEMONSTRATED BY ORAL SEMAGLUTIDE WERE DRIVEN BY A STATISTICALLY SIGNIFICANT REDUCTION IN CARDIOVASCULAR DEATH OF 51%."WE ARE VERY ENCOURAGED THAT PIONEER 6 DEMONSTRATED CARDIOVASCULAR SAFETY AS WELL AS A SIGNIFICANT REDUCTION IN BOTH CV AND ALL-CAUSE MORTALITY" CSO SAYS.  Full Article

Novo Nordisk Announced Headline Results From Pioneer 9, In Japanese Adults With Type 2 Diabetes
Thursday, 22 Nov 2018 11:30am EST 

Nov 22 (Reuters) - Novo Nordisk A/S ::ANNOUNCED HEADLINE RESULTS FROM PIONEER 9, IN JAPANESE ADULTS WITH TYPE 2 DIABETES.TRIAL SUCCESSFULLY ACHIEVED ITS PRIMARY OBJECTIVE.ORAL SEMAGLUTIDE DEMONSTRATES GREATER REDUCTIONS IN HBA1C AND BODY WEIGHT COMPARED TO VICTOZA IN JAPANESE PEOPLE WITH TYPE 2 DIABETES.  Full Article

Novo Nordisk And Embark Enter Collaboration To Discover Obesity And Metabolic Disease
Friday, 2 Nov 2018 04:07am EDT 

Nov 2 (Reuters) - Novo Nordisk A/S ::SAYS EMBARK AND NOVO NORDISK ENTER COLLABORATION TO DISCOVER NOVEL THERAPEUTICS FOR OBESITY AND METABOLIC DISEASE.  Full Article

Aeterna Zentaris Announces Novo Nordisk To Acquire Rights To Macrilen In U.S. And Canada
Thursday, 1 Nov 2018 08:00am EDT 

Nov 1 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES NOVO NORDISK TO ACQUIRE RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - NOVO NORDISK WILL ACQUIRE FROM STRONGBRIDGE BIOPHARMA PLC ITS RIGHTS TO MACRILEN IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - HAS LICENSED RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA TO STRONGBRIDGE BIOPHARMA.  Full Article

Novo Nordisk CEO Says To Double UK Inventories Ahead Of Potential Hard Brexit
Thursday, 1 Nov 2018 03:45am EDT 

Nov 1 (Reuters) - Novo Nordisk A/S CEO Lars Fruergaard Jorgensen said on Thursday::NOVO NORDISK CEO SAYS WITH REGARDS TO BREXIT WE WILL MAKE SURE WE HAVE MORE THAN DOUBLED OUR INVENTORIES IN THE UK BY THE TIME OF A POTENTIAL HARD BREXIT.NOVO NORDISK CEO SAYS NO PLANS FOR FURTHER MEASURES WITH REGARDS TO LAY-OFFS IN 2019.  Full Article

Novo Nordisk, Sanofi must face lawsuit over insulin pricing: judge

A federal judge on Friday cleared the way for consumers to proceed with a proposed class action accusing drug manufacturers Sanofi SA and Novo Nordisk of fraudulently inflating prices for insulin.